Cytokine responses in very low birth weight infants receiving glutamineenriched-enteral nutrition
Introduction
very low birth weight (vlbw) infants are susceptible to glutamine depletion, as placental supply ceases at birth, tolerance of enteral nutrition is limited and parenteral nutrition does not contain glutamine for solubility and stability reasons. in studies in vlbw infants, neu et al. 1 and our group 2 have found that glutamine-enriched enteral nutrition between day 3 and 30 of life decreased the incidence of serious infections. other studies of enteral 3 and parenteral 4, 5 glutamine supplementation in vlbw infants could not confirm this finding, possibly because of differences in supplementation method, supplementation dose and definition of infections. the mechanism underlying the beneficial effect of glutamine supplementation on infectious morbidity is not fully understood, but may include the enhancement of antimicrobial activity of the immune system.
Glutamine is used at a high rate by cells of the immune system as a source of energy, a precursor for protein synthesis and a donor of nitrogen for the synthesis of pyrimidines, nucleotides and amino sugars. 92, 93 experimental studies have indicated that the presence of glutamine in vitro increases the cytokine production of t-lymphocytes following stimulation with various mitogens. 25, 94, 95 a subset of t-helper cells denoted as t helper type 1 (th1) cells, is implicated in the cell-mediated resistance to infections, whereas th2 cells are involved in the regulation of antibody responses. the th subsets can be differentiated based on the production of a specific panel of cytokines. it has been shown that glutamine supplementation increased the th1 response in septic mice 96 and in adult trauma patients. 97 the th1 response is characterized by the production of interferon gamma (inf-γ), tumor necrosis factor alpha (tnf-α) and interleukin 2 (il-2). to date, the effect of glutamine supplementation on cytokine responses in vlbw infants has not been studied.
we hypothesized that the lower infection rate in vlbw infants receiving glutamine-enriched enteral nutrition was associated with enhanced th1 cytokine responses. therefore, as part of our randomized controlled trial of glutamine-enriched enteral nutrition in vlbw infants, 2 we determined cytokine responses by cytometric bead array (cba) following in vitro stimulation of whole blood cells. ifn-γ, tnf-α and il-2 (representative for the th1 response) and il-4, il-5 and il-10 (representative for the th2 response) were determined at three time points throughout the study period. furthermore, we evaluated the potential contributive role of other perinatal factors on the development of cytokine responses in vlbw infants.
Patients and methods

Patients
infants with a gestational age (Ga) ≤32 weeks or a birth weight (bw) ≤1500 grams who were admitted to the level iii neonatal intensive care unit (nicu) of the vu university medical center, amsterdam, were eligible for participation in the study. exclusion criteria were major congenital or chromosomal anomalies, death within 48 hours after birth, transfer to another hospital within 48 hours after birth, and admission from an extraregional hospital. the national central committee on research involving human subjects and the medical-ethical review board of our hospital approved the study protocol. written informed consent was obtained from all parents.
the study is registered in the current controlled trials database [isrctn3254583].
Randomization, blinding, and treatment
after assignment to 1 of 3 birth weight strata (≤799 g, 800-1199 g, and ≥1200 g), the infants were randomly allocated within 48 hours of birth to receive either enteral glutamine supplementation or isonitrogenous control supplementation. an independent researcher used a computer-generated randomization table based on blocks of 4 (nutricia nederland bv, Zoetermeer, the netherlands) to assign infants to treatment a or b, which corresponded to batch numbers on the nutrition products. investigators, parents, and medical and nursing staff were unaware of treatment allocation. the code for the batch numbers was broken after data analysis was performed. the glutamine powder contained 82% l-glutamine and 18% glucose (15.5% n, by wt; 371 kcal/100 g), whereas the isonitrogenous control powder contained 100% l-alanine (15.7% n, by wt; 435 kcal/100 g) (nutricia nederland bv). the 2 powders were indistinguishable by appearance, color, and smell. during the study period, both powders were monitored for stability and microbiological contamination.
the supplementation was administered in increasing doses between days 3 and 30 of life to a maximum of 0.3 g/kg/day in the glutamine-supplemented group. initially, the supplementation dose was based on birth weight. after 2 weeks, the dose was adjusted to the actual weight of the infants. two members of the nursing staff added the supplementation daily to breast milk or to preterm formula (nenatal ® ; nutricia nederland bv). each 100 ml of preterm formula provided 78 kcal, 2.1 g protein (casein-whey protein ratio 40:60), 4.4 g fat, and 7.5 g carbohydrate. the preterm formula did not contain free l-glutamine or free l-alanine. when infants were transferred to a general hospital ward before the end of the study, the protocol was continued under supervision of the principal investigator (avdb). 
Cytokine responses
blood samples for in vitro stimulation were obtained at 3 time points: before start of the study (t=0), at day 7 (t=1) and 14 (t=2) after birth. to guarantee accuracy and reliability of the cytokine response analyses, samples were treated under standardized conditions, immediately after withdrawal. as a consequence, cytokine responses were not determined when infants were transferred to a general hospital ward before the end of the study. heparinized blood was diluted 1:1 in sterile medium (rpmi 1640 without l-glutamine, Gibco, paisley, united Kingdom) and duplicate samples were incubated for 24 hours at 37 o c in the presence of anti(α)-cd3/α-cd28 (central laboratory of the netherlands red cross blood transfusion service, amsterdam, the netherlands) or Eschericia coli lipopolysaccharide (lps) (concentration 1:1000 both). after incubation, supernatants were collected and stored at -20 o c until analysis.
ifn-γ, tnf-α, il-2, il-4, il-5 and il-10 were determined by cba, according to instructions of the manufacturer (bd biosciences, alphen aan den rijn, the netherlands). the assay sensitivity was 40 pg/ml for all cytokines. the results were generated in a graphic format using the standard cba analysis software.
as nearly all measured il-4 levels were below the detection limit of 40 pg/ml (after incubation with both α-cd3/α-cd28 or lps), an additional enzyme-linked immunosorbent assay (elisa) for il-4 was performed according to instructions of the manufacturer (peliKine compact human il-4 elisa, sanquin reagents, amsterdam, the netherlands).
nutritional and clinical characteristics of the infants at the time of blood sampling were assessed, including exclusive breast milk feeding, administration of parenteral nutrition, nutritional intake, presence of a serious infection and administration of dexamethason. a serious infection was defined as sepsis, meningitis, pyelonephritis, pneumonia or arthritis as diagnosed by a combination of clinical signs and a positive culture <48 hrs preceding the blood sampling.
Nutritional support
protocol guidelines for the introduction of parenteral and enteral nutrition followed current practice at our nicu. parenteral nutrition was started at day 2 and was advanced gradually until amino acid intake reached 2.5 g/kg at day 6. parenteral nutrition was discontinued when enteral feeding reached a volume of approximately 150 ml/kg/d. 1. each 100 ml of parenteral nutrition, an all-in-one mixture provided by the hospital pharmacy, contained 54 kcal, 8.5 g glucose, 1.7 g amino acids, and1.7 g lipids. if necessary, glucose, amino acids, and lipids were given in separate solutions.
Guidelines for the introduction of enteral nutrition were as follows: 1) minimal enteral feeding was started at day 1 (6-12ml/d); 2) enteral nutrition was advanced either from day 3 or from day 5 in case of a bw <10th percentile, 98 Ga <26 weeks, apgar score <6 at 5 min, ph <7.10 or base deficit >10 mmol/l in arterial cord blood; and 3) feeding was advanced at a dose of approximately 20ml/kg/day to a maximum of 150ml/kg/d (based on actual weight). enteral feeding was reduced or withheld in case of gastric residuals (more than the total volume of past 2 feedings), bilious residuals, emesis, ileus, or necrotizing enterocolitis (bell stage ≥ii). 99 when the signs of feeding intolerance resolved, feeding was advanced within 2 days to the volume given before reduction or withholding. a feeding schedule was proposed on the basis of each infant's bw and the feeding guidelines. however, the staff of our nicu had the final responsibility for the administration of parenteral nutrition and the advancement of enteral feeding.
Statistical analysis
the sample size of 102 infants was based on the sample size calculation for the primary outcome of the main trial (time to full enteral feeding). 2 all infants were considered for assessment of cytokine responses. data are presented as means (sd) or medians (range) dependent on the distribution of the particular variable. perinatal and nutritional characteristics were analyzed with a student's t test, a mann-whitney U test and a chi-square test or fisher's exact test for continuous normally distributed, nonparametric continuous, and dichotomous data, respectively. in the primary analysis, generalized estimating equations for longitudinal analysis were used to analyze changes in cytokine responses over time. 100 this method takes into account the dependency of the observations within a patient and the fact that samples may not be available at each time point. as we used both cord, arterial, venous and capillary blood samples for cytokine response analysis, an adjustment was made for the kind of blood drawn. a logarithmic transformation was performed before analysis, as plasma cytokine concentrations had a skewed distribution. in additional analyses, we made a correction for the presence of a serious infection (≤48 hours preceding the sample) and administration of dexamethason (in the week preceding the sample). furthermore, we determined the effect of antenatal administration of corticosteroids, the presence of chorioamnionitis (histological diagnosis), mode of delivery, gestational age and birth weight on cytokine responses. all statistical analyses were performed on an intention-to-treat basis. a two-tailed p value <0.05 was considered significant. we used spss 11.0 (spss inc, chicago, il) and stata 7.0 (statcorp lp, college station, tx, usa) for data analyses. reasons for not participating in the study were: no informed consent (n=48), participation in another trial (n=32), transfer from an extraregional hospital (n=29), transfer to a regional hospital within 48 hours (n=18), death < 48 hours (n=12) and severe congenital malformations chapter 4-i 43 (n=6). after randomization, 5 infants with severe congenital malformations were excluded from the study (2 and 3 infants in glutamine and control group, respectively). patient characteristics were not different in glutamine-supplemented (n=52) and control (n=50) groups, nor were nutrition and study supplementation time points (Table 1) . nutritional and clinical characteristics at the time cytokine responses were determined, are presented in Table 2 . missing data were mainly due to the intention to perform no additional punctures for research purposes (no sample) or transfer to another hospital. at t=1, we found that more infants in the glutamine-supplemented group had been transferred to a general hospital ward in comparison to the control group (p=0.03). furthermore, at t=1 and t=2 in relatively more infants in the control group no blood sample was drawn, because the sample only would have served a research and not a clinical purpose (p=0.02 and p=0.05, at t=1 and t=2, respectively). blood samples were taken at 1.9 ± 1.0 (t=0), 7.0 ± 0.8 (t=1) and 14.1 ± 0.9 (t=2) days after birth.
cytokine responses following incubation with α-cd3/α-cd28 or lps, as analyzed by cba, were not different over time comparing glutamine-supplemented and control groups (Figure 1) . for il-5 and il-2 only levels following incubation with α-cd3/α-cd28 are presented, as following incubation with lps il-5 and il-2 levels were below the detection limit (40 pg/ml) in ≥85% of the cases. Figure 2 shows that the il-4 levels following incubation with α-cd3/α-cd28 or lps, as measured by elisa, were not different in glutamine-supplemented and control groups. in in general, following incubation with α-cd3/α-cd28, ifn-γ (p=0.001), tnf-α (p=0.002) and il-2 levels decreased (p<0.001), whereas il-10 (p<0.001) and il-5 (p<0.001) levels increased Chapter 4-I. . whole blood cytokine responses whole blood cytokine responses following incubation with anti(α)-cd3/α-cd28 (A) and Eschericia coli lipopolysaccharide (lps) (B) in glutamine-supplemented (black bars) and placebo groups (white bars), as measured by cytometric bead array. following incubation with lps only the results of ifn-γ, tnf-α and il-10 are presented, as ≥85% of the samples had il-5 and il-2 levels below the detection limit. bars indicate median values and error bars 75 th percentile. time points: before start of the study (t=0), at day 7 (t=1) and 14 (t=2) after birth. at t=0, n=39 and n=47; t=1, n=25 and n=34; t=2, n=16 and n=23 in glutaminesupplemented and control group, respectively. Generalized estimating equations were used to assess differences between glutamine-supplemented and control group at baseline and for changes over time (t=0), at day 7 (t=1) and 14 (t=2) after birth. at t=0, n=39 and n=47; t=1, n=25 and n=34; t=2, n=16 and n=23 in glutamine-supplemented and control group, respectively. Generalized estimating equations were used to assess differences between glutamine-supplemented and control group at baseline and for changes over time (compared with baseline values). whole blood cytokine responses in septic mice receiving enteral glutamine supplementation and found increased ifn-γ and decreased il-4 production. 96 in addition, in adult trauma patients enteral glutamine supplementation lead to decreased infectious morbidity in combination with increased in vitro ifn-γ and preserved il-4 production capacity. 97 in this study, cytokine responses were determined in isolated peripheral mononuclear blood cells following stimulation with phytohemagglutinin. comparison of all studies is hampered by differences in study populations and methods to determine cytokine responses. in our study, stimulation with α-cd3/α-cd28 or lps resulted in strong cytokine responses with large interindividual differences, which may explain why we did not find a stimulating effect of glutamine-enriched enteral nutrition on th1 cytokine responses. this may indicate that immune response patterns with α-cd3/α-cd28, ifn-γ, tnf-α and il-2 decreased and il-10 and il-5 levels increased over time. in addition, the ifn-γ to il-4 ratio decreased over time in both glutamine-supplemented and control groups (data not shown). following incubation with lps, cytokine levels and consequently the ifn-γ to il-4 ratio did not change between start and end of the study. regarding these contrasting results, data obtained using mitogenic stimulation or exposure to lps should be taken with caution as they do not necessarily reflect the physiological situation. in addition, the study period of two weeks may have been to short to investigate the neonatal development of cytokine response patterns. furthermore, in our study, perinatal factors (e.g. the presence of chorioamnionitis, caesarean section, and gestational age) did not systematically influence some aspects of our study design need to be addressed. as the sample size calculation was based on the primary outcome of the main trial (feeding tolerance), the sample size of the study may have been insufficient to detect a difference in cytokine responses between glutamine-supplemented and control groups. 2 in addition, in a statistically significant larger percentage of infants in the glutamine-supplemented group (at t=1 and t=2) no blood sample was drawn for ethical reasons, although the absolute number of infants without a sample was not different in glutamine-supplemented and control groups. this finding is explained by the fact that in the glutamine-supplemented group more infants were transferred to a general hospital at t=1, and consequently, less samples were available for cytokine analysis. the difference between glutamine-supplemented and control groups was not statistically significant and may be explained by the fact that infants in the glutamine-supplemented group had a tendency of fewer days on ventilator support. 2 this difference in need for ventilator support did not result in a statistically significant difference in median age at discharge from the nicu: 20 and 27.5 days in glutamine and control groups, respectively. 2 these results are in accordance with a previous study on hospital costs that showed a lower intensity of care in vlbw infants that received enteral glutamine supplementation. 113 although these results may have lead to attrition bias, the differences in cytokine responses between both treatment groups were small and it is unlikely that additional samples in the glutamine-supplemented group at t=1 would have changed the results of the study significantly. furthermore, the cytokine concentrations were measured at one time point in culture and in response to a single dose of the stimuli. as a consequence, it was not possible to determine cytokine production kinetics or sensitivity to the stimuli. finally, in our previous study, infectious morbidity was defined as ≥1 serious infection during the complete study period. in the current study, we assessed cytokine responses at 3 time points. for table 2, only serious infections ≤48 hours preceding cytokine response analysis were taken into account. in addition, results of a small number of infants with a serious infection at a blood sampling day were excluded from analysis since no blood sample was available.
these factors may in part explain why we were not able to establish a relation between cytokine responses and decreased infectious morbidity in vlbw infants receiving glutamine-enriched enteral nutrition.
in conclusion, our study shows that glutamine enriched-enteral nutrition in vlbw infants does not enhance th1 cytokine responses, as determined following in vitro whole blood stimulation with α-cd3/α-cd28 or lps. a possible explanation for the lower infection rate in infants receiving glutamine-enriched enteral nutrition, may be that glutamine-enriched enteral nutrition only influences the mucosal and not the systemic immune system. in addition, in our study perinatal factors did not systematically influence the development of cytokine responses in vlbw infants, which may indicate that these immune response patterns are primarily determined by individual (genetic) predisposition.
